ADVERTISEMENT
ADVERTISEMENT

NIH AIDS vaccine trial nixed

The National Institute of Allergy and Infectious Disease (NIAID) announced today (July 17) that it will not conduct a trial of an HIV vaccine that its own Vaccine Research Center (VRC) developed. It was known as the PAVE 100 trial. "Based on the available scientific information, NIAID has decided that the VRC vaccine regimen did not warrant a trial of this size and scope and that PAVE 100 will not proceed," the NIAID said in a linkurl:press release;http://www3.niaid.nih.gov/news/newsreleases/20

Bob Grant
Bob Grant

Bob Grant is Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer.

View full profile.


Learn about our editorial policies.

The National Institute of Allergy and Infectious Disease (NIAID) announced today (July 17) that it will not conduct a trial of an HIV vaccine that its own Vaccine Research Center (VRC) developed. It was known as the PAVE 100 trial. "Based on the available scientific information, NIAID has decided that the VRC vaccine regimen did not warrant a trial of this size and scope and that PAVE 100 will not proceed," the NIAID said in a linkurl:press release;http://www3.niaid.nih.gov/news/newsreleases/2008/pave100.htm. The trial, which was to be carried out by the linkurl:Partnership for AIDS Vaccine Evaluation;http://www.hivpave.org/ (PAVE) and sponsored by NIAID, involved administering a recombinant vaccine based on adenovirus type 5 (Ad5) to 2,400 US men who have sex with other men. The PAVE 100 vaccine was similar to a Merck vaccine involved in a failed trial that was linkurl:halted;http://www.the-scientist.com/blog/display/53633/ last year, except that researchers planned to give a single dose of the...

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
ADVERTISEMENT